Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N38G | ISIN: US29772L1089 | Ticker-Symbol:
NASDAQ
06.06.25 | 15:30
17,110 US-Dollar
-0,93 % -0,160
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ETON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ETON PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ETON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue1
29.05.Eton Pharmaceuticals stock rises on FDA approval of KHINDIVI2
ETON PHARMACEUTICALS Aktie jetzt für 0€ handeln
29.05.Eton Pharma wins FDA nod for oral hydrocortisone solution1
29.05.Eton Pharmaceuticals: H.C. Wainwright erhöht Kursziel auf 35 US-Dollar-
29.05.Eton Pharmaceuticals stock target raised to $35 by H.C. Wainwright1
29.05.FDA Approves Eton Pharma's KHINDIVI For Pediatric Adrenocortical Insufficiency1
28.05.Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI (hydrocortisone) Oral Solution193• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone)...
► Artikel lesen
28.05.Eton Pharmaceuticals, Inc. - 8-K, Current Report1
14.05.A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts1
13.05.Eton Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
13.05.Eton Pharmaceuticals, Inc. - 8-K, Current Report2
13.05.Eton Pharmaceuticals Reports First Quarter 2025 Financial Results138Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully...
► Artikel lesen
12.05.A Look Ahead: Eton Pharmaceuticals' Earnings Forecast2
01.05.Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 20251
28.04.Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment1
28.04.Eton Pharmaceuticals, Inc. - 8-K, Current Report-
28.04.Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)178- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch - DEER PARK, Ill., April 28, 2025 (GLOBE...
► Artikel lesen
01.04.Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma3
01.04.Eton Pharmaceuticals, Inc. - 8-K, Current Report1
01.04.Eton Pharmaceuticals Out-Licenses International Rights to Increlex236DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
► Artikel lesen
Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1